Owkin

Paris, France All France companies → — Founded 2016

AI Research Lab Biotech / Drug Discovery

Series B

Website Claim this company

Products

Owkin

Drug Discovery & Research

Owkin develops AI solutions for drug discovery and real-world evidence, leveraging federated learning across hospital networks to accelerate biomedical research and clinical insights.

See all 1 product →

About Owkin

Owkin is a French-American ‘TechBio’ company that leverages artificial intelligence (AI) and federated learning to revolutionize drug discovery, clinical development, and diagnostics. The company’s core mission is to untangle the complexities of biology to accelerate medical breakthroughs and bring new diagnostics and drugs to patients faster. Owkin’s AI models are trained on high-quality, multimodal patient data from a global federated network of over 800 hospitals and research centers, ensuring data privacy while unlocking valuable insights.

For physicians, Owkin’s technology offers several key advancements. Their AI-powered diagnostics, some of which are CE-marked for clinical use in Europe, aim to provide faster and more accurate diagnoses, screen for biomarkers, and predict patient outcomes such as survival, relapse, and treatment response. This can lead to more informed and targeted treatment options. Owkin also develops AI agents, such as the Pathology Explorer, which can identify cell types, locations, and biomarkers from digital pathology images, potentially accelerating drug discovery and clinical trial design. The company’s approach emphasizes ethical and responsible AI, with a commitment to transparency in how diagnostic insights are generated. Owkin’s ultimate goal is to build an autonomous AI Scientist that can automate biopharma R&D and support clinical research, continuously improving through real-world patient data.

Focus Areas

AI-driven drug discovery clinical trial optimization AI diagnostics federated learning precision medicine oncology biomarker identification digital pathology biomedical research generative biology

Business Intelligence

Technology

Federated learning, causal AI, agentic AI infrastructure, OwkinZero (biological reasoning AI model), MOSAIC (proprietary platform for multimodal patient data), K Pro (AI Scientist co-pilot for biopharma R&D)

What Physicians Need to Know

Specialization: Healthcare AI & Biotech

Owkin is a French-American 'TechBio' company that integrates causal AI and federated learning to accelerate drug discovery, clinical development, and diagnostics. They aim to identify new treatments, optimize clinical trials, and develop AI diagnostics.

Key Differentiator: Federated Learning

Owkin's core differentiator is its federated learning approach, which allows AI models to be trained on real-world patient data across a global network of over 800 hospitals and research centers without the data ever leaving the hospital firewalls. This addresses critical privacy concerns (e.g., GDPR, HIPAA compliance) and enables collaboration on larger, more diverse datasets.

Technology Stack: Multimodal AI & Agentic AI

Owkin operates a multimodal AI engine that converts pathology slides, genomic profiles, and clinical records into predictive models. They leverage spatial omics and have integrated spatial transcriptomics into their AI stack for high-resolution mapping of tumor microenvironments. Owkin is also pioneering 'agentic AI' with products like K Pro, an AI Scientist for biopharma decision-making, and Pathology Explorer, an AI agent for advanced pathology analysis.

Products & Platforms

Key offerings include Owkin Studio (now Owkin Connect) for collaborative data science, and diagnostic products like MSIntuit CRC for AI-driven biomarker pre-screening. They also have OwkinZero, a biological reasoning AI model, and K Pro, an agentic AI for biology that supports research, data analysis, and visualization.

Research & Development Focus

Owkin's R&D focuses on advancing generalizable AI for digital pathology, AI-powered spatial transcriptomics, and federated learning for biomedical research, as well as prototyping agentic AI co-pilots for scientists. Their long-term goal is to develop Biological Artificial Superintelligence (BASI) to fundamentally understand disease biology.

Physician Tip

For physicians, Owkin's solutions offer several advantages. Their AI-powered diagnostics, such as MSIntuit CRC, can enhance digital pathology workflows by screening for biomarkers and predicting outcomes, providing a fuller picture of a patient's disease and treatment options. The use of federated learning means that AI models are trained on diverse, real-world patient data from a vast network of hospitals, leading to more robust and generalizable models that can improve the personalization of medical care. This approach also ensures patient privacy and data security, which is paramount in healthcare. Furthermore, Owkin's agentic AI tools, like Pathology Explorer, can assist in analyzing tumors and microenvironments, extracting biomarkers, and generating hypotheses, which can accelerate drug discovery and clinical trial design, ultimately leading to better and faster treatment options for patients. The aim is to provide support to human clinicians, enhancing their diagnostic, prognostic, and predictive capabilities.

Owkin's platform and AI agents are designed for integration into existing healthcare workflows. Their Pathology Explorer AI agent, for instance, is accessible through Anthropic's Claude for Healthcare and Life Sciences, allowing seamless integration into Claude workflows without requiring system overhauls. Their federated learning software, Owkin Connect, supports machine learning collaborations between hospitals, research centers, and data scientists with complementary datasets. Owkin emphasizes interoperable, validated platforms that integrate multi-omic and imaging data. They also offer their K Pro agentic AI to partners to support their research, data analysis, and visualization.

Products by Owkin

1 product in the directory

Owkin

Drug Discovery & Research

Owkin develops AI solutions for drug discovery and real-world evidence, leveraging federated learning across hospital networks to accelerate biomedical research and clinical insights.

What the Web Says

Owkin is generally viewed as a pioneering company in the healthcare AI and federated learning space, with a strong scientific foundation and a mission to accelerate medical research. Employee reviews highlight a positive work environment, intellectual challenge, and a strong company culture, though some point to rapid growth challenges and potential for high workload. Product-specific reviews are less prevalent on general review sites, but the company's collaborations and scientific publications suggest a positive reception within the research community.

Overall: Positive

Strengths

Pioneering work in federated learning and AI for medical research
Strong scientific expertise and research-driven culture
Positive and collaborative work environment (employee reviews)
Meaningful mission with potential for significant impact on healthcare
Good opportunities for learning and professional growth
Competitive compensation and benefits (employee reviews)

Limitations

Rapid growth can lead to organizational challenges or high workload
Potential for long hours due to demanding projects
Specific product reviews are not widely available on general platforms
Some employees note a need for clearer communication during rapid expansion
Highly specialized field may not appeal to all job seekers
Reliance on external partnerships for data access can be complex

Based on reviews from: Glassdoor, Reddit, Healthcare IT News (general industry perception), Company website (for mission and approach)

Last updated: 2026-09-10

Videos

News, demos, and interviews about Owkin.

Loading videos...

Videos load interactively. If none appear, search YouTube for Owkin →

View all on YouTube

Press & Coverage

Owkin

Owkin Partners with Boehringer Ingelheim to Accelerate Drug Discovery with AI

Owkin has signed a licensing agreement with Boehringer Ingelheim for its AI Scientist, K Pro, and multimodal patient data to accelerate drug discovery in oncology and immunology. This collaboration builds on a 2025 pilot project and aims to enhance data-driven pharmaceutical research.

2026-09

Owkin

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Owkin announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, supported by a five-year license for Owkin's AI Scientist, K Pro. This expands on an existing strategic partnership focused on oncology and immunology.

2026-06

Owkin

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca

Owkin has entered a three-year licensing agreement with AstraZeneca to build biopharma agents as part of their use of K Pro, Owkin's AI Scientist. This agreement aims to integrate AI into AstraZeneca's decision workflows for drug discovery and development.

2026-05

Owkin

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing

Owkin announced the spin-out of Waiv, its diagnostics division, with $33 million in financing. Waiv will focus on AI-powered precision testing for patient identification in clinical settings and trials.

2026-03

Owkin

Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological Breakthroughs

Owkin launched its agentic infrastructure for biology, making its AI agents available to the healthcare ecosystem to accelerate biomedical research. This initiative, announced at the JPM Healthcare Conference, aims to achieve Biological Artificial Super Intelligence (BASI).

2026-01

Owkin

Owkin: Pioneering Biological Artificial Superintelligence for the Future of Medicine

Owkin is pioneering Biological Artificial Superintelligence (BASI) through its autonomous AI Scientist, K Pro, to revolutionize drug discovery, diagnostics, and clinical decisions. K Pro analyzes multimodal patient data from vast hospital networks and is continuously refined by experts.

2026-07

Startup Intros

Owkin Funding: $334M Raised, Series B (2022)

Owkin has raised a total of $334.1 million across 8 funding rounds, with its most recent being an $80 million Series B round in June 2022. The company leverages federated learning to analyze patient data for drug discovery and clinical research.

2026-07

Owkin

Breakthrough in medical research published in Nature Medicine

Owkin published groundbreaking research in Nature Medicine demonstrating the first use of federated learning to train deep learning models on histopathology data from multiple hospitals. This research predicted the response of triple-negative breast cancer patients to chemotherapy while protecting patient privacy.

2023-01

Frequently Asked Questions

What specific AI products does Owkin offer for healthcare providers and administrators?

Owkin offers AI solutions primarily focused on accelerating drug discovery, optimizing clinical trials, and developing AI diagnostics. Their products include 'K Pro,' an AI scientist for pharmaceutical research and strategic decision-making, and 'Pathology Explorer,' an AI agent that analyzes digital pathology images to identify cell types, locations, and biomarkers.

How does Owkin ensure compliance with healthcare data privacy regulations like GDPR and HIPAA?

Owkin prioritizes patient privacy by using privacy-enhancing technologies like federated learning, which allows AI models to be trained on decentralized data from hospitals without centralizing or directly accessing sensitive patient information. They also state their commitment to complying with applicable regulations such as GDPR and the UK Data Protection Act 2018, and have a Data Protection Officer for patient inquiries.

What is the typical pricing model for Owkin's AI solutions for hospitals and healthcare systems?

While specific pricing details are not publicly disclosed, Owkin's platform is described as a free service for hospitals, with their primary client relationship being with the pharmaceutical industry through licensing predictive algorithms. For organizations needing advanced features and premium support for products like K Pro, an enterprise version is available, and interested parties are encouraged to contact their team for a personalized demo.

What kind of support does Owkin provide to healthcare organizations implementing their AI technologies?

Owkin offers support to its partners, including access to K Pro to aid in research, data analysis, and visualization. For enterprise users of K Pro, they provide 'Katalyst sessions,' which are dedicated workshops where the Owkin team collaborates directly with organizations to accelerate onboarding and tailor the platform to specific needs.

What partnerships does Owkin have with healthcare institutions and pharmaceutical companies?

Owkin has established a global network of over 100 research centers and collaborates with numerous academic institutions and hospitals, including Leeds Teaching Hospitals NHS Trust and NHS Lothian. They also have strategic alliances with major pharmaceutical companies such as Sanofi, AstraZeneca, Bristol-Myers Squibb, and MSD to improve therapeutic programs and accelerate drug discovery.

What is Owkin's company stability and funding status, and what is their long-term vision?

Owkin was founded in 2016 and has raised over $354 million in funding, achieving a valuation of over $1 billion in 2021. Their long-term vision is to build Biological Artificial Superintelligence (BASI) to automate biopharma R&D and connect research directly to patient care, aiming to untangle the complexity of biology beyond human limits.

How does Owkin validate its AI models and ensure their accuracy and reliability in clinical settings?

Owkin emphasizes rigorous validation of its AI models, including external clinical validation with diverse data to ensure accuracy, reliability, and generalizability to real-world patient samples. Their products undergo robust multicentric and international validations across various hardware and IT settings, and they continuously monitor deployed AI medical devices for performance.